Ocugen, Inc. (OCGN): Capital Expenditures
$185.0K
Year ended 2025-12-31
$153.0K
Trailing 12 months to 2026-06-30
-65.4%
3-year compound annual growth
-9.6%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $185.0K | -94.5% | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | $3.38M | -67.7% | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | $10.48M | +135.0% | 2025-03-05, From 2023-01-01 |
| 2022-12-31 | $4.46M | +374.7% | 2024-04-16, From 2022-01-01 |
| 2021-12-31 | $939.0K | +205.9% | 2023-02-28, From 2021-01-01 |
| 2020-12-31 | $307.0K | +923.3% | 2022-02-28, From 2020-01-01 |
| 2019-12-31 | $30.0K | n/c | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $77.4K | -72.0% | 2020-03-27, From 2018-01-01 |
| 2017-12-31 | $276.0K | -13.8% | 2019-03-22, From 2017-01-01 |
| 2016-12-31 | $320.0K | -83.6% | 2018-03-15, From 2016-01-01 |
| 2015-12-31 | $1.95M | -41.3% | 2017-03-16, From 2015-01-01 |
| 2014-12-31 | $3.32M | n/a | 2016-03-10, From 2014-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Ocugen, Inc. (OCGN) | 2025-12-31 | $185.0K | -94.5% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $4.53M | -37.9% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $134.0K | -42.7% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $23.0K | n/a |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $914.0K | -51.9% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $128.0K | +392.3% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $532.0K | -77.2% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $5.95M | +715.5% |
| Aligos Therapeutics, Inc. (ALGS) | 2024-12-31 | $130.0K | +584.2% |
Compare OCGN, PRME, CGON, ZEOX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗